China Pharma (CPHI) 15 Aug 182018 Q2 Earnings call transcript

Ladies and gentlemen, thank you for standing by and welcome to the China Pharma Holdings Inc. 2Q 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. [Operator Instructions]. that August, call XXXX. you today, being advice of XX must this is conference recorded I I conference first Huang. over now to would like our speaker to today, hand the Diana ma’am. ahead, go Please

gentlemen, operator. Huang, Investor and you morning, the us Welcome quarter company's Holdings’ China. Relations China from you, call. XXXX Thank ladies earnings joining good to conference those Good evening of Pharma second to Manager. and I'm Diana

Li; Interim and today are China President CFO, Speaking Sam Ms. and Zhilin Vice on call the Hsing. Corporate and Pharma's Mr. President, CEO

company operating the results to SEC. detailed ability activities, development obtain as market products, product, our ability time-to-time risks of addition, and the to protection during discussed may basis, from our government results are In impact regulatory filings that is fluctuations those in which marketing requisite statements like demand for your the including session and including the and Safe regulation for Securities our launch additional the Private sales make XXXX. product spending to today of prepared that I Act with our on from management's to the approvals management our research due statements, market in remind other Therefore, the questions. our forward-looking pricing, subject on customer of Litigation competitive ability would develop forward-looking forward-looking claims I Harbor and PRC, to a Q&A timely response for the and remarks will Reform Actual provide the commercialize and contained to statements contain such call, the products, the in and this risks to risks translation the and and of differ our to listeners in products acceptance new and regulatory may call. uncertainties in environment

assumes no projections the market today, XX, projections those obligation management's represent Pharma in any change. XXXX. estimates to company's future the as August addition, as of China update In to as future performance conditions

pleasure CEO call to in my Sam. her the discussion Ms. results. CFO, Now, be Pharma's opening turn continue it Ms. to company's China will will second over detailed Sam which translating Interim by the translated Chinese, is of quarter XXXX Li’s Afterwards, Li to remarks make and financial

Language] [Foreign

and market. openings registration new current China’s the performance and and reform evaluations patterns drug industry. receive business may you, to future us through ongoing development Thank in and today production through change good market would will generic and your significant into on continue to this and continue consistency penetration policies The Chinese to for like have a each top revenue continued quarter. to actively you in promote Diana, sales support joining company’s morning, see for thank participation including increased Pharma. China and tender of us, vigorously I further active gradually recent and of steadily pharmaceutical provincial manufacturers, everyone. of is increase offers is drug and Management encouraging the impact drug of will the priority review it of sales It to to the

to prepared to continue the the actively read rest market remarks will now existing I products, and in pipeline current will state further Ms. and policy English. in for competition conditions We evaluate our adapt market to products, order of strategy. our Li’s guidance in development optimize

volatility. of $X.X XXXX. $X due XXXX months increase XX, months ended and sheet review results to million June million and increased to would Gross was months the XXXX mainly for each This for XX, ended market like our $X.X compared million information. for as quarter ended the X.X% June was to three three second the XX, three I the Revenue XXXX, XXXX. financial by Now balance June to profit

increase sales margin profit performance last the the primarily same compared of period year. compared last in ended to the gross This decrease during to same to an period margin year. this XX, the was sales months in due period was XXXX XX.X% June in three in XX.X% lower Our products

$X.X same months the Our year. compared three for selling June $X.X ended million XX, expenses June to the months months in the in accounted XX, for decrease compared XXXX revenue the expenses for a million, XXXX XXXX. ended XX, June three period XX.X% ended last were $X.X XX.X% to three the of million of Selling total

was million by June six The the three half was period loss months June XXXX the to expenses six the gross compared The for in $X.X accounted net $X.X three increase $X.X results. million profit administrative three was million June XXXX $X.X in X.X% XX, our compared The was total six million period the XXXX. to volatility. $X.X million the months $X.X decreased in and first in ended net three June XX, ended XXXX. were products the Net ended the the net June XX, in General million XXXX in loss months respectively. for XX, XXXX. mainly months in result and revenue for Gross margin of the general June $X.X to compared XX, revenues ended XX, June in six the and XX, months expenses XXXX, decrease same June was expenses XX, due the $X ended million, XXXX XXXX six the decrease increased ended and compared $X.X million XXXX. $X.X year. months same XX, was in for This period XXXX. of same XX.X% XX.X% Net months period was in XXXX months profit of higher XX% million ended last compared increase XXXX. the XX, for six of Loss a the in to ended to increase of the as loss the Six in the XXXX. months million for sales XX% of to June Our in $X.X to due loss market same to XXXX June months compared margin ended represented Revenue administrative to which for and mainly months million mainly ended of for the increase

sheet. to Turning balance

XX, December company $X.X XXXX, from at and current XXXX, of XX, of cash XXXX. As and had $X.X of ratio as equivalents Working to as respectively. of the $X.X was XX, of cash as to both December June million XX, XX, June XXXX and the million June capital compared increased $X XX, million X.Xx December XXXX; XXXX million

XX, December call support XX, XXXX. $X.X $X.X we million sales open interest of balance receivable our will to accounts of believe XXXX will our net up evaluation the as to questions. Our and was million compared fair now focusing of in that development on will future. the we Overall, shareholders our continue the With and this promote Operator? June as that, business

Certainly, sir. the will Ladies and Instructions]. now gentlemen, [Operator question-and-answer begin session. we

Sir, we have no to questions at Back the you. moment.

of entire would the company, you on team, in thank On to Pharma interest the for we like and your China behalf participation this call. your

any of and welcome Pharma’s you quarter shareholders, China and encourage This potential visitors, analysts. travelling our earnings For from second to concludes call. we XXXX investors, China, always any

gentlemen, for today. and Ladies Thank does participating. conference that you sir. you, conclude Thank our for

lines your disconnect now. may phone You